Benefit of PD-1/PD-L1 treatment lasts beyond discontinuation

New research from the Dana-Farber Cancer Institute suggests that blocking the PD-1 pathway could lead to a sustained clinical benefit in patients, potentially making continuous dosing of PD-1 or PD-L1 inhibitors to treat cancer unnecessary.

Current standard of care for renal cell carcinoma (RCC) patients is to administer PD-1/PD-L1 inhibitors on a continuous basis until disease progression or development of toxicities...